Publications associées à Hypertriglycéridémie

Dopamine Transporter, PhosphoSerine129 alpha-Synuclein and alpha-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice

The G2019S mutation in leucine rich-repeat kinase 2 (LRRK2) is a major cause of familial Parkinson's disease. We previously reported that G2019S knock-in mice manifest dopamine transporter dysfunction and phosphoSerine129 alpha-synuclein (pSer129 alpha-syn ...

MDPI2022

Mitochondrial respiratory chain dysfunction disrupts intracellular cholesterol homeostasis

Christopher Tadhg James Wall

Mitochondrial diseases are rare and severe conditions with debilitating symptoms. Biochemical defects in mitochondria however are common. The difference between these two frequencies is suspected to lie in the capability of the cells to adapt to the homeos ...

EPFL2022

Follicular regulatory helper T cells control the response of regulatory B cells to a high-cholesterol diet

Nikolaos Stergiopoulos

Aims B cell functions in the process of atherogenesis have been investigated but several aspects remain to be clarified. ...

OXFORD UNIV PRESS2021

Cardiotrophin-1 Deficiency Abrogates Atherosclerosis Progression

Nikolaos Stergiopoulos, Rodrigo Araujo Fraga Da Silva

Cardiotrophin-1 (CT-1) is associated with cardiovascular (CV) diseases. We investigated the effect of CT-1 deficiency in the development and progression of atherosclerosis in double knockout Apoe(-/-)ct-1(-/-) mice. Apoe(-/-) C57Bl/6 or Apoe(-/-)ct-1(-/-) ...

Nature Research2020

Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis

Nikolaos Stergiopoulos

Endocannabinoids modulate atherogenesis by triggering different receptors. Recently, orphan G protein-coupled receptors (GPRs) were suggested to be activated by endocannabinoids, possibly regulating vasorelaxation. Here, we investigated whether GPR55 antag ...

Schattauer Gmbh-Verlag Medizin Naturwissenschaften2016

Treatment with KLEPTOSE (R) CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response

Anne-Laure Gassner

The ability of pharmacological agents to target both "classical" risk factors and inflammation may be key for successful outcomes in the prevention and treatment of atherogenesis. Among the promising drugs interfering with cholesterol metabolism, we invest ...

Elsevier Science Inc2015

Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice

Nikolaos Stergiopoulos, Rafaela Fernandes Da Silva, Maiia Bragina, Fabiana Pereira Da Costa Fraga

Angiotensin (Ang) II contributes to the development of atherosclerosis, while Ang-(1-7) has atheroprotective actions. Accordingly, angiotensin-converting enzyme 2 (ACE2), which breaks-down Aug 11 and forms Ang-(1-7), has been suggested as a target against ...

Elsevier2015

Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments

Pierre Magistretti, Aurélie Delacrétaz

Weight gain is a major health problem among psychiatric populations. It implicates several receptors and hormones involved in energy balance and metabolism. Phosphoenolpyruvate carboxykinase 1 is a rate-controlling enzyme involved in gluconeogenesis, glyce ...

Lippincott, Williams & Wilkins2015

Insights into the antiatherogenic molecular mechanisms of andrographolide against Porphyromonas gingivalis-induced atherosclerosis in rabbits

Amer Ashrafi

Atherosclerosis is the commonest and most important vascular disease. Andrographolide (AND) is the main bioactive component of the medicinal plant Andrographis paniculata and is used in traditional medicine. This study was aimed to evaluate the antiatherog ...

Springer2014

Secure & Lightweight Distance-Bounding

Serge Vaudenay, Aikaterini Mitrokotsa, Ioana Cristina Carlson

Distance-bounding is a practical solution to be used in security-sensitive contexts, mainly to prevent relay attacks. The main challenge when designing such protocols is maintaining their inexpensive cryptographic nature, whilst being able to protect again ...

2013